Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q1 2026 (March 31)9holders
1new positions
0sold out
$20.06avg. 13F price*
At the end of Q1 2026, 9 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 0 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($10.0M), Ra Capital Management, L.P. ($6.7M) and Affinity Asset Advisors, LLC ($4.9M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $43K |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 2,127 shares bought and 2,966 shares sold, net −839 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $10.0M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $6.7M |
| Affinity Asset Advisors, LLC | — | No change | 245,000 | $4.9M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 99,999 | $2.0M |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $1.9M |
| Aristeia Capital, L.L.C. | — | No change | 15,708 | $343K |
| Vestcor Inc | — | Reduce -30.8% | 6,666 | $131K |
| Wolverine Asset Management LLC | — | New | 2,127 | $43K |
| UBS Group AG | — | No change | 396 | $8K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.